The present study investigated the histopathologic and radiographic features of stage 3 bisphosphonate-associated osteonecrosis of the jaw (BAONJ) in patients who were treated with partial mandibulectomies. Bisphosphonates had been orally administered to 10 patients with osteoporosis and intravenously administered to 1 patient with metastatic carcinoma. On radiographic images, massive osteolysis and periosteal bone formations were conspicuous, and a thin mandibular cortical width was observed in 5 of 10 osteoporosis patients despite the previous use of bisphosphonate. Microscopically, the mandibulectomy specimens of the patients could be divided into 4 distinct layers. Although there were few differences in overall histologic features betwe...
Objective. To describe the histological features of bone tissue harvested from patients affected by ...
AIM: A series of 5 patients with osteonecrosis of the jaws possibly related to the use of bisphospho...
Bisphosphonates (BPs) are used to treat metabolic bone diseases, such as osteoporosis. In this study...
Introduction: Patients undergoing bisphosphonate therapies may develop jaw lesions, mainly consistin...
ObjectiveTo assess the main clinical, radiographic, and histopathologic features of patients with bi...
BACKGROUND AND PURPOSE: Bisphosphonates are drugs that decrease bone turnover by inhibiting osteocla...
Bisphosphonate therapy is recommended in prostate cancer patients with bone metastases, even in the ...
A retrospective study was conducted of the records and panoramic radiographs of 35 patients treated ...
Background. Bisphosphonates are drugs used in the treatment of lytic bone metastases, multiple myelo...
BACKGROUND: In recent years, several cases of mandibular necrosis associated with long-term use ...
Abstract: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is characterized as exposed bone ...
Objectives. Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisph...
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) was first mentioned in the literature in 200...
To understand the clinical features of osteonecrosis of the jaw after bisphosphonates use for therap...
Bisphosphonate-related osteonecrosis of the jaws (BON), first described in 2003, is gaining importan...
Objective. To describe the histological features of bone tissue harvested from patients affected by ...
AIM: A series of 5 patients with osteonecrosis of the jaws possibly related to the use of bisphospho...
Bisphosphonates (BPs) are used to treat metabolic bone diseases, such as osteoporosis. In this study...
Introduction: Patients undergoing bisphosphonate therapies may develop jaw lesions, mainly consistin...
ObjectiveTo assess the main clinical, radiographic, and histopathologic features of patients with bi...
BACKGROUND AND PURPOSE: Bisphosphonates are drugs that decrease bone turnover by inhibiting osteocla...
Bisphosphonate therapy is recommended in prostate cancer patients with bone metastases, even in the ...
A retrospective study was conducted of the records and panoramic radiographs of 35 patients treated ...
Background. Bisphosphonates are drugs used in the treatment of lytic bone metastases, multiple myelo...
BACKGROUND: In recent years, several cases of mandibular necrosis associated with long-term use ...
Abstract: Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is characterized as exposed bone ...
Objectives. Recently, jawbone osteonecrosis has been reported as a potential adverse effect of bisph...
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) was first mentioned in the literature in 200...
To understand the clinical features of osteonecrosis of the jaw after bisphosphonates use for therap...
Bisphosphonate-related osteonecrosis of the jaws (BON), first described in 2003, is gaining importan...
Objective. To describe the histological features of bone tissue harvested from patients affected by ...
AIM: A series of 5 patients with osteonecrosis of the jaws possibly related to the use of bisphospho...
Bisphosphonates (BPs) are used to treat metabolic bone diseases, such as osteoporosis. In this study...